23 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.
F. Hoffmann-La Roche
Novel fatty acid binding protein 4 (FABP4) inhibitors: virtual screening, synthesis and crystal structure determination.
Chinese Academy of Sciences
Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins.
University of Minnesota
Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
Bristol-Myers Squibb Pharmaceutical Research Institute
Truxillic acid monoamides as fatty acid binding protein 5 inhibitors.
Stony Brook University
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review.
Universita degli Studi di Catania
NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein.
Bristol-Myers Squibb Pharmaceutical Research Institute
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. An update from 2017 to early 2022.
University of Catania
Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target.
Biovitrum
Development of FABP4/5 inhibitors with potential therapeutic effect on type 2 Diabetes Mellitus.
Fudan University
Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation.
Chinese Academy of Sciences
Identification of new dual FABP4/5 inhibitors based on a naphthalene-1-sulfonamide FABP4 inhibitor.
Fudan University
SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.
Stony Brook University
Synthesis, ß-glucuronidase inhibition and molecular docking studies of hybrid bisindole-thiosemicarbazides analogs.
Universiti Teknologi Mara
Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof
Bayer Intellectual Property
Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
Merck Sharp & Dohme
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.
University of Massachusetts